N.A. Beelen
Recent publications
-
Barbeau, L. M. O., Beelen, N. A., Savelkouls, K. G., Keulers, T. G. H., Wieten, L., & Rouschop, K. M. A. (2025). MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer. PLOS ONE, 20(2), Article e0316716. https://doi.org/10.1371/journal.pone.0316716More information about this publication
-
Beelen, N. A., Valckx, V. T. C., Bos, G. M. J., & Wieten, L. (2024). Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy. Best Practice & Research Clinical Haematology, 37(3), Article 101568. https://doi.org/10.1016/j.beha.2024.101568More information about this publication
-
Beelen, N. A., Molenbroeck, S. J. J., Groeneveld, L., Voorter, C. E., Bos, G. M. J., & Wieten, L. (2024). HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma. Immunogenetics, 76(3), 155-164. https://doi.org/10.1007/s00251-024-01336-wMore information about this publication
-
Beelen, N. A. (2024). Natural killer cells in the tumor microenvironment: Enhancing immunotherapy by exploring the communication between NK cells and tumor cells. [Doctoral Thesis, Maastricht University]. Maastricht University. https://doi.org/10.26481/dis.20240426nbMore information about this publication
-
Beelen, N. A., Aberle, M. R., Bruno, V., Olde Damink, S. W. M., Bos, G. M. J., Rensen, S. S., & Wieten, L. (2023). Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Frontiers in Immunology, 14(1), Article 1133796. https://doi.org/10.3389/fimmu.2023.1133796More information about this publication
-
Beelen, N. A., Ehlers, F. A. I., Bos, G. M. J., & Wieten, L. (2023). Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunology Immunotherapy, 72(4), 797-804. https://doi.org/10.1007/s00262-022-03299-xMore information about this publication
-
Beelen, N. A., Ehlers, F. A. I., Kooreman, L. F. S., Bos, G. M. J., & Wieten, L. (2023). An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue. In C. Thomas, & L. Galluzzi (Eds.), The Immunological Synapse Part A (1 ed., Vol. 173, pp. 133-153). Academic Press. https://doi.org/10.1016/bs.mcb.2022.05.001More information about this publication
-
Beaumont, J. E. J., Beelen, N. A., Wieten, L., & Rouschop, K. M. A. (2022). The Immunomodulatory Role of Hypoxic Tumor-Derived Extracellular Vesicles. Cancers, 14(16), Article 4001. https://doi.org/10.3390/cancers14164001More information about this publication
-
Sheffer, M., Lowry, E., Beelen, N., Borah, M., Naffar-Abu Amara, S., Mader, C. C., Roth, J. A., Tsherniak, A., Freeman, S. S., Dashevsky, O., Gandolfi, S., Bender, S., Bryan, J. G., Zhu, C., Wang, L., Tariq, I., Kamath, G. M., Simoes, R. D., Dhimolea, E., ... Mitsiades, C. S. (2021). Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nature Genetics, 53(8), 1196-1206. https://doi.org/10.1038/s41588-021-00889-wMore information about this publication
-
Ehlers, F. A., Beelen, N. A., van Gelder, M., Evers, T. M. J., Smidt, M. L., Kooreman, L. F. S., Bos, G. M. J., & Wieten, L. (2021). ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response. Cancers, 13(13), Article 3232. https://doi.org/10.3390/cancers13133232More information about this publication